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Twenty-two consecutive carbapenem-resistant enterobacterial isolates were recovered from patients hospitalized between Janu-
ary and April 2013 in different units at a university hospital in Istanbul, Turkey. These were Klebsiella pneumoniae isolates pro-
ducing the carbapenemases OXA-48, NDM-1, and KPC-2, Enterobacter cloacae isolates producing NDM-1, and Escherichia coli
isolates producing OXA-48. Most of the OXA-48-producing K. pneumoniae and all the NDM-1-producing E. cloacae were clon-
ally related. The NDM-1-producing E. cloacae isolates recovered from a single neonatal intensive care unit corresponded to a
single cluster, highlighting the spread of that clone in that setting.
Carbapenem-hydrolyzing -lactamases belonging to Amblerclasses A, B, and D have been reported worldwide among
Enterobacteriaceae (1, 2). In Turkey, the wide dissemination of
OXA-48-producing isolates (from Klebsiella pneumoniae, Esche-
richia coli, Citrobacter freundii, and Enterobacter cloacae) has been
demonstrated, deﬁning this country as being endemic forOXA-48
(3–5). Apart from OXA-48 producers, isolates producing other
types of carbapenemases (NDM-1, IMP-1, and KPC-2) were re-
cently identiﬁed in Turkey as well. The non-OXA-48-producing
carbapenemase producers reported from Turkey are the follow-
ing: six NDM-1-producing K. pneumoniae isolates (6, 7), four
IMP-1-producing K. pneumoniae isolates (7, 8), and a single KPC-
2-producing K. pneumoniae isolate (9).
The spread of NDM-1-producing Enterobacteriaceae is now
considered to be almost global (10). However, only a few out-
breaks of NDM-1 producers have been reported. So far, most of
the reports from many countries have been scattered and corre-
sponded mainly to importation cases (1).
Our study was designed to evaluate retrospectively the occur-
rence of carbapenemase-producing Enterobacteriaceae in a uni-
versity hospital in Istanbul, Turkey. An increased number of car-
bapenem-resistant isolates recovered from patients hospitalized
in the neonatal intensive care unit (NICU) during a short period
prompted us to perform such a study.
All enterobacterial isolates presenting with reduced suscepti-
bility to imipenem (MIC  0.5 g/ml) were collected between 1
January and 1 May 2013 (a 4-month period), consisting of a total
of 22 isolates. The MICs of the carbapenems were determined by
the Etest (AB bioMérieux, La Balme-les-Grottes, France) on
Mueller-Hinton agar plates at 37°C, and the results of susceptibil-
ity testing were interpreted according to CLSI guidelines (11).
Those isolates were recoveredmostly fromurine samples, and also
from rectal swabs (Table). All isolates were considered to be col-
onizers. These were K. pneumoniae (n  12), E. cloacae (n  8),
and E. coli (n  2) (Table 1). The isolates were resistant to all
-lactams, including carbapenems for most isolates (Table 2).
However, some isolates were still categorized in the susceptible
range for carbapenems (Table 2). In addition, they were mostly
resistant to aminoglycosides, ﬂuoroquinolones, chlorampheni-
col, sulfonamides, fosfomycin, and nitrofurantoin. All except two
of them had low MIC values (0.5 g/ml) for colistin, as mea-
sured by the Etest.
Carbapenemase detection was performed using the Carba NP
test (12), and positive results were obtained for the 22 isolates.
Thus, PCR assays were carried out with a series of primers de-
signed to detect Ambler class A, B, and D carbapenemase genes,
i.e., blaKPC, blaIMP, blaVIM, blaNDM, and blaOXA-48 (13), followed by
sequencing of the PCR amplicons. Two isolates were positive for
blaKPC-2, 12 for blaNDM-1 gene, and eight for blaOXA-48 (Table 1).
None of the isolates coharbored two carbapenemase genes. Note
that the two KPC-2-producing isolates were K. pneumoniae, the
12 NDM-1-producing isolates were K. pneumoniae (n 4) and E.
cloacae (n 8), and the eight OXA-48-producing isolates were K.
pneumoniae (n 6) and E. coli (n 2) (Table 1).
Genotyping was performed to evaluate the clonal relationship
of the K. pneumoniae and E. cloacae isolates by pulsed-ﬁeld gel
electrophoresis (PFGE) (14), and K. pneumoniae isolates were ad-
ditionally genotyped by multilocus sequence typing (MLST), as
described previously (15). The two KPC-2-producing K. pneu-
moniae isolates were clonally related and belonged to the sequence
type 307 (ST307). The four NDM-1-producing K. pneumoniae
isolates were clonally unrelated, belonging to ST15, ST45, ST278,
and ST1059. The eight NDM-1-producing E. cloacae isolates were
clonally undistinguishable by PFGE, thus corresponding to a sin-
gle clone. Finally, the six OXA-48-positive K. pneumoniae isolates
were all clonally related and belonged to ST101 (Table 1).
Interestingly, looking at the hospitalization wards from which
the patients originated, it appeared that a cluster of colonizing
NDM-1-producing E. cloacae isolates occurred in the NICU, with
a total of eight neonates harboring this same resistant strain. Sim-
ilarly, the two patients colonized with the KPC-2-producing K.
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pneumoniae isolates had been hospitalized in the same ward (plas-
tic surgery). Regarding the dissemination of the ST101 and OXA-
48-producing K. pneumoniae isolates (ﬁve patients colonized in
four distinct wards), a nosocomial route of dissemination might
be also suspected. However, this hypothesis is not obvious consid-
ering that OXA-48-producing K. pneumoniae are very widespread
in Turkey, and taking into account the heterogeneity observed in
terms of antibiotic resistance for those isolates, the MICs of car-
bapenems, and coresistance markers (Table 2). Interestingly,
ST101 and OXA-48-producing K. pneumoniae isolates have been
reported in Libya (16) and were at the origin of an outbreak in
Spain (17). In contrast, and even if OXA-48-producing K. pneu-
moniae isolates of many different STs have been identiﬁed in Tur-
key (18), that speciﬁc clone was never identiﬁed in that country.
Considering the recent and frequent transfers of Libyan patients
to Turkey, and in particular in the hospital where those samples
have been recovered, this might explain the emergence of that
speciﬁc clone.
Note that the majority of the NDM-1-positive isolates, regard-
less of their clonal lineage and of the species to which they be-
longed, were multidrug resistant. In particular, most of them co-
expressed the extended-spectrum -lactamase CTX-M-15 and
the narrow-spectrum -lactamase OXA-1, as identiﬁed by PCR
and sequencing (19) (Table 1). In addition, since all NDM-1-
positive isolates were resistant at a high level to all aminoglyco-
sides, a search of 16S rRNA methylase-encoding genes was per-
formed as described previously (20). The results showed that all
those isolates (eight E. cloacae and the four K. pneumoniae iso-
lates) were positive for the rmtC gene (21).
In order to evaluate whether the cooccurrence of the blaNDM-1
and the rmtC genes might be related to the spread of a speciﬁc
plasmid,mating-out assayswere performedusing all those isolates
as donors and with E. coli J53 as the recipient, as described previ-
ously (22). Interestingly, E. coli transconjugants coproducing
NDM-1 and RmtC were obtained for all the isolates, and a single
plasmid of ca. 150 kb was identiﬁed in all transconjugants. That
plasmid additionally conferred resistance to rifampin to all
transconjugants. However, it did not harbor the blaCTX-M-15 gene,
in accordance with the susceptibility to aztreonam (a substrate
spared by NDM-1) (23) observed for all E. coli transconjugants.
Attempts to type this plasmid using the PCR-based replicon typ-
ing (24) remained unsuccessful. PCR mapping was performed to
identify the genetic sequences surrounding the blaNDM-1 gene in
all positive isolates. The same structure was found, with the
blaNDM-1 gene preceded by a truncated version of ISAba125, fol-
lowed by the bleMBL gene encoding resistance to bleomycin (25).
Similar structures were identiﬁed previously in different species
from different countries (19).
Our study reports an outbreak ofNDM-1-producing E. cloacae
in a NICU setting and describes the emergence of plasmid-
mediated 16S rRNA methylases in Turkey. Here, the RmtC
enzyme was involved and was encoded by a gene located on the
same plasmid carrying the blaNDM-1 gene. Such an association
between those two genes was previously reported in a single K.
pneumoniae isolate from India (19) and in a series of K. pneu-
moniae isolates from Kenya (26). A 150-kb and untypeable plas-
mid coharboring the two geneswas similarly identiﬁed here and in
the Indian isolate. Thewide spread ofmultidrug-resistantNDM-1
producers in a NICU setting is extremely worrisome, since infec-
tions developed by those immunocompromised patients are very
TABLE 2 MICs of carbapenems and coresistance to non--lactam antibiotics
Patient/strain
no. Isolate
Carbapenemase
produced
MIC (g/ml) of carbapenemsa
CoresistancesbIMP MER ERT
1 K. pneumoniae NDM-1 2 4 16 TET SUL RIF AMK GEN TOB
2 K. pneumoniae OXA-48 1 1 4 SUL AMK GEN TOB FQ FOS
3 K. pneumoniae OXA-48 0.5 2 8 TET GEN TOB FQ CHL
4 K. pneumoniae OXA-48 0.5 2 8 TET GEN TOB FQ CHL
5 E. coli OXA-48 0.5 0.25 0.5 SUL RIF FOS
6 E. cloacae NDM-1 8 4 8 TET SUL RIF AMK GEN TOB
7 E. cloacae NDM-1 8 4 8 TET SUL RIF AMK GEN TOB
8 E. cloacae NDM-1 8 4 8 TET SUL RIF AMK GEN TOB
9 E. cloacae NDM-1 8 4 8 TET SUL RIF AMK GEN TOB
10 E. cloacae NDM-1 8 4 8 TET SUL RIF AMK GEN TOB
11 E. cloacae NDM-1 8 4 8 TET SUL RIF AMK GEN TOB
12 E. coli OXA-48 0.5 0.25 0.5 SUL RIF FOS
13 E. cloacae NDM-1 8 4 8 TET SUL RIF AMK GEN TOB
14 E. cloacae NDM-1 8 4 8 TET SUL RIF AMK GEN TOB
15 K. pneumoniae OXA-48 1 4 8 TET SUL RIF GEN TOB FQ
16 K. pneumoniae NDM-1 4 4 8 TET SUL RIF AMK GEN TOB COL
17 K. pneumoniae NDM-1 4 4 4 TET SUL RIF AMK GEN TOB
18 K. pneumoniae NDM-1 4 2 8 TET SUL RIF AMK GEN TOB
19 K. pneumoniae OXA-48 1 4 16 TET RIF GEN TOB FOS COL
20 K. pneumoniae OXA-48 8 8 16 TET SUL GEN TOB FQ CHL FOS
21 K. pneumoniae KPC-2 2 4 8 RIF FQ FOS
22 K. pneumoniae KPC-2 2 4 8 RIF FQ FOS
a IMP, imipenem; MER, meropenem; ERT, ertapenem.
b TET, tetracycline; SUL, sulfonamides; RIF, rifampin; AMK, amikacin; GEN, gentamicin; TOB, tobramycin; FQ, ﬂuoroquinolones (ciproﬂoxacin and oﬂoxacin); COL, colistin
(indicated when the MIC was not0.5 g/ml); CHL, chloramphenicol; FOS, fosfomycin.
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difﬁcult to treat. While this work was in progress, an outbreak of
NDM-1-producingK. pneumoniaewas also reported in a neonatal
unit located in Bogotá, Colombia (27). In that study, two out of
the six infected newborns died. The strain involved corresponded
to ST1043, which is unrelated to the STs identiﬁed in our study.
In many countries, the occurrence of NDM-1 producers in hos-
pitalized patients ismostly related to previous patient hospitalization
on the Indian subcontinent. Nevertheless, the ﬁrst case of NDM-1-
producing K. pneumoniae in Turkey was related to a transfer from
Iraq (8). While this work was in progress, another study showed
the emergence of NDM-1-producing K. pneumoniae isolates in a
Turkish hospital located in Kayseri, the center of Turkey, which is
800 km from Istanbul (7), further emphasizing the actual NDM-1
producer problem in Turkey and therefore identifying a possible
hidden reservoir for those multidrug-resistant isolates. In that
study, as in ours, the origin of the NDM-1-producing isolates is
unknown. Altogether, those studies indicate that the spread of
NDM-1 producers in the Middle East may be more important
than was suspected and is now likely out of control.
This clinical experience was interesting since an outbreak was
suspected as soon as two similar carbapenem-resistant E. cloacae
isolates were recovered from two different patients in the NICU,
which is a 30-bed unit. Nasal and rectal swabs were obtained from
all 30 patients, and 10 more swabs were obtained from the incu-
bators and environment (a total of 70 surveillance cultures). None
of the swabs from the incubators and environment grew carbap-
enem-resistant Enterobacteriaceae (CRE). In order to detect the
ﬂaws in work practices causing this colonization, a hospital video
surveillance system was used, and signiﬁcant compromises in the
infection control procedures were identiﬁed, especially during
night shifts. A detailed and rigorous infection control training
program was therefore performed, in which all staff participated.
Contact isolation precautions were strictly implemented with all
the patients who were positive for CRE, and after 30 to 45 days,
there were no patients in the NICU who were infected or colo-
nized with any CRE organism, and there has not been a single case
since then (8 months). This further shows that complementary
works between the clinical andmicrobiological unitsmay contrib-
ute signiﬁcantly to preventing the spread of CRE.
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